Our PreTarg-it® Strategy: EnsuringSite-directed Radioactive Delivery
Leveraging our expertise in antibody engineering, we've created the modular PreTarg-it® platform. It employs bispecific antibodies for pre-targeted radioimmunotherapy, targeting challenging cancers. Our bispecific antibodies ensure optimal tumor penetration and retention, enhancing site-restricted payload delivery.
Our PreTarg-it® strategy separates the delivery of the tumor-targeting agent (“Compound 1”) from the radioactive agent (“Compound 2”). This approach features a two-part system: a tailored bispecific antibody (“Compound 1”) that targets a specific tumor marker, and a small, radiolabeled molecule (“Compound 2”) designed for therapeutic or diagnostic purposes. By postponing the radioligand’s administration until after the antibody has been adequately cleared from the bloodstream and has concentrated within the tumor, we can ensure targeted delivery. Upon administration, Compound 2 quickly enters the tumor, attaches to Compound 1, while any unbound Compound 1 is swiftly removed through the kidneys. This method drastically reduces radiation exposure to healthy organs. The modular “target X × payload Y” concept allows specific targeting of tumor antigens with toxic payloads of different substance classes, like radionuclides, immunomodulators, and (encapsulated) toxins.
Our PreTarg-it® strategy separates the delivery of the tumor-targeting agent (“Compound 1”) from the radioactive agent (“Compound 2”). This approach features a two-part system: a tailored bispecific antibody (“Compound 1”) that targets a specific tumor marker, and a small, radiolabeled molecule (“Compound 2”) designed for therapeutic or diagnostic purposes. By postponing the radioligand’s administration until after the antibody has been adequately cleared from the bloodstream and has concentrated within the tumor, we can ensure targeted delivery. Upon administration, Compound 2 quickly enters the tumor, attaches to Compound 1, while any unbound Compound 1 is swiftly removed through the kidneys. This method drastically reduces radiation exposure to healthy organs. The modular “target X × payload Y” concept allows specific targeting of tumor antigens with toxic payloads of different substance classes, like radionuclides, immunomodulators, and (encapsulated) toxins.
Harnessing the Full Potential of Therapeutics With Site-Directed Precise Medicines
Leveraging our PreTarg-it® platform, we are progressing with four research programs aimed at providing therapeutic solutions for difficult-to-treat solid tumors in the pancreas, ovary, lung, and stomach.
These programs focus on the development of bispecific antibodies that target specific tumor markers such as oxMIF, mesothelin (MSLN), folate receptor-α (FRα), and HER2.
